 |
Cash-Rich Drugmakers Eye Mergers or Acquisitions
Andrew Witty, the new chief executive of giant GlaxoSmithKline , surveys the wreckage of the global financial meltdown and sees an upside. With pharmaceutical stocks at record lows, it's a good time to acquire biotech companies and other assets that could drive Glaxo's growth for years. Its midsize rival Wyeth is also on the prowl -- but there's a difference. Faced with a shrinking market ... |
|
|
Biotech startups may get a head start
 |
The Oklahoma City Redevelopment Authority and the Presbyterian Health Foundation are negotiating a plan that would create a "mobile incubator” to attract and then retain startup biotech companies.The deal, which was approved in concept Wednesday by the redevelopment authority (a trust run by the Urban Renewal Authority), calls for tax increment finance funds to be used to buy space from the ... |
|
MedPredict's Rheumatology Panel Analyzes Rheumatoid Arthritis, Lupus and Gout Markets and Pipelines Following ACR ...
 |
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis , lupus and gout therapies. |
|
|
|
| MORE TOP STORIES |
|
| MORE DOMAINS |
|
|
